About: Laboratory Testing Methods for Novel Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Laboratory Testing Methods for Novel Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Laboratory Testing Methods for Novel Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)
Creator	Currier, Arthur D'cruz, Roshan Labarge, Mark Pritchett, James Sampson, Valerie Seshadri, Vasudevan
source	Medline; PMC; WHO
abstract	Following the first reports of coronavirus disease-19 (COVID-19) by China to the World Health Organization (WHO) on 31st December 2019, more than 4,302,774 novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) cases have been reported by authorities in 212 countries and territories by 12th May 2020. The outbreak and spread of COVID-19 worldwide, highlights the critical need for developing rapid and accurate diagnostic testing methods for emerging human coronavirus (CoV) infections. Testing is crucial to track the spread of disease during a pandemic, and to swiftly permit public health interventions including isolation, quarantine, and appropriate clinical management of afflicted individuals. The key components of viral diagnostic tests are (1) collection of the appropriate sample (blood, nasal swab, and throat swab), (2) availability of the genetic and proteomic sequences of the novel virus for analysis, and (3) rapid and accurate laboratory testing methods. The current gold standard for the molecular diagnosis of SARS-CoV-2 infection is the real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for the qualitative and quantitative detection of viral nucleic acids. Other relevant laboratory methods include enzyme-linked immunoassays (EIA) for viral antibody and antigen detection, and serum viral neutralization (SVN) assays for antibody neutralization determination. The challenges faced in developing a diagnostic test for a novel pathogen are the ability to measure low viral loads for early detection, to provide low or no cross-reactivity with other viral strains and to deliver results rapidly. Several point-of-care molecular devices are currently being integrated for fast and accurate diagnosis of SARS-CoV-2 infections. This review discusses the current laboratory methods available to test for coronaviruses by focusing on the present COVID-19 outbreak.
has issue date	2020-06-04(xsd:dateTime)
bibo:doi	10.3389/fcell.2020.00468
bibo:pmid	32582718
has license	cc-by
sha1sum (hex)	90e46adb07cfa781ece62dcefb59fed51dc1ce3d
schema:url	https://doi.org/10.3389/fcell.2020.00468
resource representing a document's title	Laboratory Testing Methods for Novel Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)
has PubMed Central identifier	PMC7287038
has PubMed identifier	32582718
schema:publication	Front Cell Dev Biol
resource representing a document's body	covid:90e46adb07cfa781ece62dcefb59fed51dc1ce3d#body_text
is schema:about of	named entity 'diagnosis' named entity 'nucleic acids' named entity 'point-of-care' named entity 'developing' named entity 'Methods' named entity 'KEY' named entity 'BEING' named entity '12TH' named entity 'AUTHORITIES' named entity 'ANALYSIS' named entity 'REVIEW' named entity 'PUBLIC HEALTH' named entity 'LOW' named entity 'RAPIDLY' named entity 'LOADS' named entity 'PCR' named entity 'DISEASE' named entity 'LABORATORY TESTING' named entity 'GOLD STANDARD' named entity 'CORONAVIRUSES' named entity 'INTEGRATED' named entity 'APPROPRIATE' named entity 'ABILITY TO' named entity 'INTERVENTIONS' named entity 'QUANTITATIVE' named entity 'LABORATORY METHODS' named entity 'DEVELOPING' named entity 'QUARANTINE' named entity 'FACED' named entity 'ACCURATE' named entity 'gold standard' named entity 'RT-PCR' named entity 'SARS-CoV-2' named entity 'disease' named entity 'viral' named entity 'viral' named entity 'faced' named entity 'track' named entity 'clinical management' named entity 'proteomic' named entity 'developing' named entity 'diagnostic test' named entity 'laboratory' named entity 'antibody' named entity 'Acute' named entity 'Novel' named entity 'human coronavirus' named entity 'SARS-CoV-2' named entity 'molecular devices' named entity 'molecular diagnosis' named entity 'point-of-care' named entity 'SVN' named entity 'RT-PCR' named entity 'accurate' named entity 'infections' named entity 'RNAs' named entity 'viral replication' named entity 'gene' named entity 'randomized clinical trial' named entity 'antibody titer' named entity 'antigens' named entity 'diagnostic testing' named entity 'SARS-CoV-2' named entity 'RT-PCR' named entity 'COVID-19' named entity 'personal protective equipment' named entity 'respiratory failure' named entity 'Plasma' named entity 'evidence-based' named entity 'antigens' named entity 'virus' named entity 'RT-PCR' named entity 'SARS-CoV' named entity 'public health emergency of international concern' named entity 'antibodies' named entity 'virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software